Reinfection versus relapse in lyme disease

New England Journal of Medicine

Volumn 367, Issue 20, 2012, Pages 1950-1951

  Steere, Allen C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; DOXYCYCLINE; PLACEBO;

ANTIBIOTIC THERAPY; ARTHRITIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; ERYTHEMA CHRONICUM MIGRANS; HUMAN; INFECTION RATE; LYME DISEASE; MOLECULAR TYPING; PRIORITY JOURNAL; REINFECTION; RELAPSE; SKIN BIOPSY; SYNOVITIS; TREATMENT DURATION;

EID: 84868702912     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1211361     Document Type: Editorial

References (11)

1. Surveillance for Lyme disease - United States, 1992-2006. MMWR Surveill Summ 2008;57(10):1-9.
2. Steere AC. Lyme disease. N Engl J Med 1989;321:586-96.
3. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089-134. [Erratum, Clin Infect Dis 2007;45:941.]
4. Nadelman RB, Wormser GP. Reinfection in patients with Lyme disease. Clin Infect Dis 2007;45:1032-8.
5. Nadelman RB, Hanincová K, Mukherjee P, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med 2012;367:1883-90.
6. Nadelman RB, Nowakowski J, Forseter G, et al. Failure to isolate Borrelia burgdorferi after antibiotic therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study. Am J Med 1993;94:583-8.
7. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med 2003;138:697-704.
8. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345:85-92.
9. Drouin EE, Seward RJ, Strle K, et al. A novel human auto-antigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease. Arthritis Rheum 2012 October 8 (Epub ahead of print).
10. Bockenstedt LK, Gonzales DG, Haberman AM, Belperron AA. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest 2012;122:2652-60.
11. Feder HM Jr, Johnson BJ, O'Connell S, et al. A critical appraisal of "chronic Lyme disease." N Engl J Med 2007;357:1422-30.